Life expectancy and cause of death in males and females with Fabry disease: Findings from the Fabry Registry

被引:251
作者
Waldek, Stephen [1 ]
Patel, Manesh R. [2 ]
Banikazemi, Matyam [3 ,4 ]
Lemay, Roberta [5 ]
Lee, Philip [6 ]
机构
[1] Salford Royal NHS Fdn Trust, Manchester M6 8HD, Lancs, England
[2] Duke Univ, Sch Med, Div Cardiovasc Med, Durham, NC USA
[3] Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA
[4] Columbia Univ Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA
[5] Genzyme Corp, Biomed Data Sci & Informat, Cambridge, MA USA
[6] Natl Hosp Neurol & Neurosurg, Charles Dent Metab Unit, London WC1N 3BG, England
关键词
alpha-galactosidase A; Anderson-Fabry disease; lysosomal storage disease; longevity; cardiovascular; ENZYME REPLACEMENT THERAPY; ANGIOKERATOMA CORPORIS DIFFUSUM; AGALSIDASE-BETA THERAPY; CLINICAL-MANIFESTATIONS; HYPERTROPHIC CARDIOMYOPATHY; ALPHA-GALACTOSIDASE; KIDNEY-DISEASE; OUTCOME SURVEY; COHORT; TRIAL;
D O I
10.1097/GIM.0b013e3181bb05bb
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Purpose: To evaluate life expectancy and cause of death among patients with Fabry disease, an X-linked lysosomal storage disorder. Methods: Data from 2848 patients in the Fabry Registry were summarized using descriptive statistics. Life expectancy at birth was compared with that of the United States general population. Results: As of August 2008, 75 of 1422 males and 12 of 1426 females in the Fabry Registry were reported to have died. The 87 deceased patients were diagnosed at a much older age than other patients in the Fabry Registry: median age at diagnosis was 40 vs. 24 years in males and 55 vs. 33 years in females. The life expectancy of males with Fabry disease was 58.2 years, compared with 74.7 years in the general population of the United States. The life expectancy of females with Fabry disease was 75.4 years, compared with 80.0 years in the United States general population. The most common cause of death among both genders was cardiovascular disease. Most (57%) patients who died of cardiovascular disease had previously received renal replacement therapy. Conclusions: Most deceased Fabry Registry patients exhibited serious cardiac and renal dysfunction. Late diagnosis may have contributed to the early deaths of these patients. Genet Med 2009:11(11):790-796.
引用
收藏
页码:790 / 796
页数:7
相关论文
共 36 条
  • [1] Agalsidase-beta therapy for advanced Fabry disease - A randomized trial
    Banikazemi, Maryam
    Bultas, Jan
    Waldek, Stephen
    Wilcox, William R.
    Whitley, Chester B.
    McDonald, Marie
    Finkel, Richard
    Packman, Seymour
    Bichet, Daniel G.
    Warnock, David G.
    Desnick, Robert J.
    [J]. ANNALS OF INTERNAL MEDICINE, 2007, 146 (02) : 77 - 86
  • [2] Natural history of Fabry renal disease -: Influence of α-galactosidase A activity and genetic mutations on clinical course
    Branton, MH
    Schiffmann, R
    Sabnis, SG
    Murray, GJ
    Quirk, JM
    Altarescu, G
    Goldfarb, L
    Brady, RO
    Balow, JE
    Austin, HA
    Kopp, JB
    [J]. MEDICINE, 2002, 81 (02) : 122 - 138
  • [3] Myofilament degradation and dysfunction of human cardiomyocytes in Fabry disease
    Chimenti, Cristina
    Halmdani, Nazha
    Boontje, Nicky M.
    DeCobelli, Francesco
    Esposito, Antonio
    Bronzwaer, Jean G. F.
    Stienen, Ger J. M.
    Russo, Matteo A.
    Paulus, Walter J.
    Frustaci, Andrea
    van der Veldent, Jolanda
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2008, 172 (06) : 1482 - 1490
  • [4] COLOMBI A, 1967, HELV MED ACTA, V34, P67
  • [5] Desnick RobertJ., 2001, The Metabolic and Molecular Bases of Inherited Disease, V8th, P3733
  • [6] Cardiovascular disease after renal transplantation
    Dimény, EM
    [J]. KIDNEY INTERNATIONAL, 2002, 61 : S78 - S84
  • [7] Cardiovascular disease and subsequent kidney disease
    Elsayed, Essam F.
    Tighiouart, Hocine
    Griffith, John
    Kurth, Tobias
    Levey, Andrew S.
    Salem, Deeb
    Sarnak, Mark J.
    Weiner, Daniel E.
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2007, 167 (11) : 1130 - 1136
  • [8] Fabry disease: Guidelines for the evaluation and management of multi-organ system involvement
    Eng, Christine M.
    Germain, Dominique P.
    Banikazemi, Maryam
    Warnock, David G.
    Wanner, Christoph
    Hopkin, Robert J.
    Bultas, Jan
    Lee, Philip
    Sims, Katherine
    Brodie, Scott E.
    Pastores, Gregory M.
    Strotmann, Joerg M.
    Wilcox, William R.
    [J]. GENETICS IN MEDICINE, 2006, 8 (09) : 539 - 548
  • [9] A phase 1/2 clinical trial of enzyme replacement in Fabry disease: Pharmacokinetic, substrate clearance, and safety studies
    Eng, CM
    Banikazemi, M
    Gordon, RE
    Goldman, M
    Phelps, R
    Kim, L
    Gass, A
    Winston, J
    Dikman, S
    Fallon, JT
    Brodie, S
    Stacy, CB
    Mehta, D
    Parsons, R
    Norton, K
    O'Callaghan, M
    Desnick, RJ
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 68 (03) : 711 - 722
  • [10] Safety and efficacy of recombinant human α-galactosidase a replacement therapy in Fabry's disease.
    Eng, CM
    Guffon, N
    Wilcox, WR
    Germain, DP
    Lee, P
    Waldek, S
    Caplan, L
    Linthorst, GE
    Desnick, RJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (01) : 9 - 16